Log in to save to my catalogue

289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malig...

289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malig...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2fdb09ee544e42f79751e40542a845ff

289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting

About this item

Full title

289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting

Publisher

London: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A316-A316

Language

English

Formats

Publication information

Publisher

London: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

BackgroundThe efficacy of T cell directed immunotherapies relies on adequate priming of T cells to tumor-specific neoantigens, which some studies have augmented with synthetic neoantigen vaccines. This is the first report of a personalized genomic vaccine (PGV-001) in multiple histologies in the adjuvant setting.MethodsTumor and germline RNA and DN...

Alternative Titles

Full title

289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_2fdb09ee544e42f79751e40542a845ff

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2fdb09ee544e42f79751e40542a845ff

Other Identifiers

E-ISSN

2051-1426

DOI

10.1136/jitc-2020-SITC2020.0289

How to access this item